Electromed Inc. reported record financial results for the second quarter (Q2) of fiscal 2026, with net revenues rising 16.3% to USD 18.9 million. Operating income for the period increased 42.4% to USD 3.6 million, reflecting an operating margin of 19.2% of net revenues. Net income reached USD 2.8 million, or USD 0.32 per diluted share, up 40.3% from the same period last year. During Q2 FY 2026, Electromed Inc. repurchased USD 2.8 million of its common stock at an average price of USD 26.16 per share, and ended the quarter with USD 13.8 million in cash and no debt. The company highlighted the success of its Triple Down on Bronchiectasis marketing campaign, aimed at increasing physician and patient awareness for its SmartVest system, targeting the approximately 800,000 diagnosed bronchiectasis patients who may benefit from the technology. Management noted that Q2 FY 2026 marked the 13th consecutive quarter of year-over-year revenue and net income growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Electromed Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210776688) on February 10, 2026, and is solely responsible for the information contained therein.